Nuzenio

Recommends Cytokinetics

Recommends Cytokinetics news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 9 latest news signals 8 publisher sources 100/100 entity strength

Latest news

Cytokinetics (CYTK) Stock Looks Near Fair Value Despite UK MYQORZO Approval - Yahoo FinanceYahoo Finance · Sat, 08 Aug 2026 11:10:15 GMT CYTK Maintained by RBC Capital -- Price Target Lowered to $112 - GuruFocusGuruFocus · Fri, 07 Aug 2026 21:26:53 GMT Cytokinetics, Incorporated Stock 12‑Month Price Target Cut to $107.65, Implies 32% Upside - TradingViewTradingView · Fri, 07 Aug 2026 10:21:18 GMT NICE recommends AstraZeneca's Calquence for two blood cancers in England and Wales - The Pharma LetterThe Pharma Letter · Thu, 06 Aug 2026 13:52:58 GMT Cytokinetics wins UK MHRA approval and NICE backing for MYQORZO (aficamten) in obstructive HCM - DealroomDealroom · Sat, 01 Aug 2026 07:14:54 GMT NICE & MHRA Accelerate Access to Cytokinetics' Myqorzo for Obstructive HCM - NAVLIN DAILYNAVLIN DAILY · Fri, 31 Jul 2026 09:18:48 GMT Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH) and Cytokinetics (CYTK) - The Globe and MailThe Globe and Mail · Fri, 31 Jul 2026 07:00:00 GMT Cytokinetics Wins UK MHRA Approval and NICE Recommendation for MYQORZO (aficamten) in Obstructive Hypertrophic Cardiomyopathy - Quiver QuantitativeQuiver Quantitative · Thu, 30 Jul 2026 07:00:00 GMT

Timeline

Sat, 08 Aug 2026 11:10:15 GMTCytokinetics (CYTK) Stock Looks Near Fair Value Despite UK MYQORZO Approval - Yahoo Finance

Fri, 07 Aug 2026 21:26:53 GMTCYTK Maintained by RBC Capital -- Price Target Lowered to $112 - GuruFocus

Fri, 07 Aug 2026 10:21:18 GMTCytokinetics, Incorporated Stock 12‑Month Price Target Cut to $107.65, Implies 32% Upside - TradingView

Thu, 06 Aug 2026 13:52:58 GMTNICE recommends AstraZeneca's Calquence for two blood cancers in England and Wales - The Pharma Letter

Sat, 01 Aug 2026 07:14:54 GMTCytokinetics wins UK MHRA approval and NICE backing for MYQORZO (aficamten) in obstructive HCM - Dealroom

Fri, 31 Jul 2026 09:18:48 GMTNICE & MHRA Accelerate Access to Cytokinetics' Myqorzo for Obstructive HCM - NAVLIN DAILY

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

Cytokinetics9 live mentions NICE7 live mentions CYTK4 live mentions MYQORZO4 live mentions Myqorzo4 live mentions Stock Looks Near2 live mentions Fair Value Despite2 live mentions UK MYQORZO Approval2 live mentions RBC Capital2 live mentions Price Target Lowered2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Recommends Cytokinetics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

8 distinct publisher/source names are currently connected to this entity page.